<div class="container">
    <div class="row">
        <div id="speaker-detail" class="col-lg-6 col-lg-offset-3">
            <div class="row">
                <button title="Close (Esc)" type="button" class="mfp-close">×</button>
                <div class="col-md-4 col-lg-4">
                    <img class="img-responsive" src="img/taiwan_industry_01.jpg" alt="" />
                    <br />
                </div>
                <div class="col-md-8 col-lg-8">
                    <h2>Karen Wen<br>溫國蘭 總經理</h2>
                    <h3>President, Mycenax Biotech Inc. 永昕生物醫藥</h3>
                    <p>Dr. Karen Wen currently serves as the President of Mycenax Biotech Inc and she is one of the founders of this company. She has 20 years experience in the biopharmaceutical industry and is well versed in drug development. Prior to founding Mycenax, she worked at Development Center for Biotechnology in Taiwan as research fellow, project leader of biomedical plan and manager of research and development for biodevice pilot plant. Her work experience included cell line evaluation, manufacturing process development, clinical trial design, quality assurance and regulatory compliance. Throughout the ten years, she has successfully led her team to execute two biopharmaceutical programs from bench into clinical stage.</p>
                    <p>Mycenax, a member of Center Laboratories group which is one of the Taiwan leading biopharmaceutical conglomerate, is positioned as biopharmaceutical company specialized in high quality and competitive cost recombinant products. In 2020, Mycenax will have 2~4 biosimilars in autoimmune indications launched and two biosimilars in oncology indications are launched through our CDMO to CMO services (contract development and manufacturing services). Two bionovels will be in early clinical phase. In the mean time, Mycenax continue to provide CDMO services with CMC expertise and PIC/S GMP production.</p>
                </div>
            </div>
        </div>
    </div>
</div>
